Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Regional Differences in Baseline Disease Characteristics and Prior Treatment in the ECZTRA 1 and ECZTRA 2 Trials

Main Article Content

Eric Simpson
Thomas Werfel
Thomas Bieber
Louise Steffensen
Alexandra Kuznetsova
Marie Østerdal
Hidehisa Saeki

Keywords

Atopic Dermatitis, Tralokinumab, Monotherapy

Abstract

Abstract not available.

References

1. Barbarot S et al. Allergy 2018; 73: 1284−1293.

2. Nutten S. Ann Nutr Metab 2015; 66(Suppl 1): 8–16.

3. Weidinger S, Novak N. Lancet 2016; 387: 1109–1122.

4. Silverberg JI et al. Ann Allergy Asthma Immunol 2018; 121: 340–347.

5. Szegedi K et al. J Eur Acad Dermatol Venereol 2015; 29: 2136–2144.

6. Popovic B et al. J Mol Biol 2017; 429: 208–219.

7. Furue K et al. Immunology 2019; 158: 281–286.

8. Tsoi LC et al. J Invest Dermatol 2019; 139: 1480–1489.

9. Bieber T. Allergy 2020; 75: 54–62.